Get the Stockscreener App
52.95
0.27%
0.14
Enliven Therapeutics Inc stock is traded at $52.95, with a volume of 368.65K.
It is up +0.27% in the last 24 hours and up +10.84% over the past month.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
See More
Previous Close:
$52.81
Open:
$53.15
24h Volume:
368.65K
Relative Volume:
0.30
Market Cap:
$3.78B
Revenue:
-
Net Income/Loss:
$-98.78M
P/E Ratio:
-31.82
EPS:
-1.6638
Net Cash Flow:
$-65.60M
1W Performance:
-0.47%
1M Performance:
+10.84%
6M Performance:
+105.39%
1Y Performance:
+141.23%
1-Day Range:
$51.74
$53.71
1-Week Range:
$51.39
$54.88
52-Week Range:
$14.79
$54.88
Enliven Therapeutics Inc Stock (ELVN) Company Profile
Name
Enliven Therapeutics Inc
Sector
Industry
Phone
720-647-8519
Address
6200 LOOKOUT ROAD, BOULDER
Compare ELVN vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ELVN
Enliven Therapeutics Inc
|
52.95 | 3.78B | 0 | -98.78M | -65.60M | -1.6638 |
VRTX
Vertex Pharmaceuticals Inc
|
477.36 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
656.01 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
918.22 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.23 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
271.77 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Enliven Therapeutics Inc Stock (ELVN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-16-25 | Initiated | Goldman | Buy |
| Dec-13-24 | Initiated | BTIG Research | Buy |
| Sep-09-24 | Initiated | H.C. Wainwright | Buy |
| Jun-11-24 | Initiated | Robert W. Baird | Outperform |
| Apr-09-24 | Initiated | Mizuho | Buy |
| Mar-29-23 | Initiated | Jefferies | Buy |
View All
Enliven Therapeutics Inc Stock (ELVN) Latest News
Goldman Sachs Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Raises Target Price to $67 - Moomoo
ELVN Maintained by Goldman Sachs -- Price Target Raised to $67.0 - GuruFocus
Enliven Therapeutics chief medical officer Collins sells $263k in shares - Investing.com UK
Enliven Therapeutics CFO Hohl sells $316,780 in stock - Investing.com India
Enliven Therapeutics chief medical officer Collins sells $263k in shares By Investing.com - Investing.com South Africa
Enliven Therapeutics CFO Hohl sells $316,780 in stock By Investing.com - Investing.com South Africa
Form 4 Enliven Therapeutics Inc For: 21 July By Investing.com - Investing.com Canada
Enliven Therapeutics Insider Sold Shares Worth $263,373, According to a Recent SEC Filing - marketscreener.com
Enliven Therapeutics Insider Sold Shares Worth $316,780, According to a Recent SEC Filing - marketscreener.com
Enliven Therapeutics (NASDAQ: ELVN) CFO sells 6,018 shares after option exercise - Stock Titan
Enliven Therapeutics, Inc. (ELVN) CMO exercises options, sells 5,000 shares - Stock Titan
Enterprise value to revenue forward of Enliven Therapeutics, Inc. – NASDAQ:ELVN - TradingView
Enliven Therapeutics (ELVN) Slides 2.88% as Stock Tests Support LevelFundamentals - dars.gov.et
Enterprise value to EBIT forward of Enliven Therapeutics, Inc. – NASDAQ:ELVN - TradingView
Price to earnings forward of Enliven Therapeutics, Inc. – BOATS:ELVN - TradingView
How Enliven Therapeutics Inc. (ELVN) Affects Rotational Strategy Timing - Stock Traders Daily
Form 144 Enliven Therapeutics For: 17 July By Investing.com - Investing.com Nigeria
Enliven Therapeutics (ELVN) investor Helen Collins plans sale of 15,000 shares - Stock Titan
Enliven Therapeutics stock hits 52-week high at 52.47 USD By Investing.com - Investing.com Nigeria
Enliven Therapeutics stock hits 52-week high at 52.47 USD - Investing.com
Enliven Therapeutics, Inc. (ELVN) Upgraded to Buy: Here's What You Should Know - MSN
H.C. Wainwright Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Raises Target Price to $64 - Moomoo
Enliven Therapeutics Inc. (ELVN) Q1 2026 Earnings: EPS Beat Driven by Lower Operating Costs, Stock Slips on Lack of Pipeline CatalystsQuarterly Earnings - dars.gov.et
Enliven Therapeutics Is Maintained at Buy by HC Wainwright & Co. - Moomoo
H.C. Wainwright raises Enliven Therapeutics price target on trial data By Investing.com - Investing.com Canada
ELVN Maintained by HC Wainwright & Co. -- Price Target Raised to $64 - GuruFocus
Insider Sell Alert: Lori Kunkel Sells 10,000 Shares of Enliven T - GuruFocus
Enliven Therapeutics (ELVN) Fell Out Of Russell Indexes, But Is The Valuation Already Rich? - simplywall.st
Enliven Therapeutics Insider Sold Shares Worth $504,903, According to a Recent SEC Filing - marketscreener.com
Enliven Therapeutics (ELVN) director sells 10,000 shares under 10b5-1 plan - Stock Titan
Enliven Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares - AOL.com
Enliven Therapeutics (ELVN) Stock Looks Overvalued As Returns Surge But Book Value Lags - Yahoo Finance
Enliven Therapeutics (ELVN) Surges Past Key Level: Biotech Momentum BuildsJurik MA - dars.gov.et
ELVN Maintained by Stifel -- Price Target Raised to $80 - GuruFocus
Stifel Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Raises Target Price to $80 - Moomoo
Medical Hedge Fund Sells 281,000 Shares of Enliven Theapeutics. Is it Time to Sell ELVN? - AOL.com
Enliven Therapeutics Inc. Q1 2026 Earnings: Better-Than-Expected Losses Highlight Clinical ProgressRevenue Beat Analysis - dars.gov.et
ELVN Maintained by Jones Trading -- Price Target Raised to $70.0 - GuruFocus
Jones Trading raises Enliven Therapeutics price target on CML trials By Investing.com - Investing.com South Africa
JonesTrading Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Raises Target Price to $70 - Moomoo
Enliven Therapeutics, Inc.(NasdaqGS:ELVN) dropped from Russell Microcap Growth Benchmark Index - marketscreener.com
Jones Trading raises Enliven Therapeutics price target on CML trials - Investing.com
Enliven Therapeutics, Inc.(NasdaqGS:ELVN) dropped from Russell 3000E Growth Benchmark - marketscreener.com
Enliven Therapeutics, Inc.(NasdaqGS: ELVN) dropped from Russell Microcap Index - marketscreener.com
Enliven Therapeutics, Inc.(NasdaqGS: ELVN) dropped from Russell 3000E Index - marketscreener.com
What to Know About This $345,000 Enliven Insider Sale as the Stock Soars 130% - Yahoo Finance
Enliven Therapeutics Inc Stock (ELVN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Enliven Therapeutics Inc Stock (ELVN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Hohl Benjamin | CHIEF FINANCIAL OFFICER |
Jul 17 '26 |
Sale |
52.64 |
6,018 |
316,780 |
46,054 |
| Collins Helen Louise | CHIEF MEDICAL OFFICER |
Jul 17 '26 |
Option Exercise |
2.48 |
5,000 |
12,400 |
30,000 |
| Collins Helen Louise | CHIEF MEDICAL OFFICER |
Jul 17 '26 |
Sale |
52.67 |
5,000 |
263,373 |
25,000 |
0.46%
0.84%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):